Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
ABSTRACTS in PERSPECTIVE - Based on presentations from the 48th Annual Meeting of the American Society of Clinical Oncology
VEGF Inhibition in Colorectal Cancer: Changing the Treatment Paradigm
Chicago, Illinois / June 1-5, 2012
EDITORIAL OVERVIEW: Prof. Dirk Arnold, MDDirector, Hubertus Wald Tumor Center, University Cancer Center Hamburg, University Hospital Eppendorf, Hamburg, Germany Hagen Kennecke, MD, MHA, FRCPCMedical Oncologist and Clinician Researcher,...
PRIORITY PRESS - 48th Annual Meeting of the American Society of Clinical Oncology
Targeting Androgen Signalling in Metastatic Castration-resistant Prostate Cancer
Chicago, Illinois / June 1-5, 2012
Chicago - Improved understanding of the mechanisms of castration-resistant prostate cancer (CRPC) has led to the recognition of the key role the androgen receptor (AR) has in disease progression. Accumulating evidence suggests that AR...
PRIORITY PRESS - 48th Annual Meeting of the American Society of Clinical Oncology
Hormone Activity Suppression in Castration-resistant Prostate Cancer
Chicago, Illinois / June 1-5, 2012
Chicago - A series of multicentre studies with agents that suppress hormone activity are expected to revise current management pathways in castration-resistant prostate cancer (CRPC). The 2 largest studies, testing different strategies in...
PRIORITY PRESS - 48th Annual Meeting of the American Society of Clinical Oncology
Continuous Benefit of VEGF Inhibition in Metastatic Colorectal Cancer
Chicago, Illinois / June 1-5, 2012
Chicago - New data extend the period in which inhibition of angiogenesis improves control of metastatic colorectal cancer (mCRC). The latest in a series of studies have indicated therapies targeted at tumour growth signalling, including the...
PRIORITY PRESS - 107th Annual Meeting of the American Urological Association
Bone-targeted Therapies for Patients with Advanced Prostate Cancer
Atlanta, Georgia / May 19-24, 2012
Atlanta - Most patients with advanced prostate cancer will experience at least one skeletal-related event (SRE) without bone-directed therapy. In men with castration-resistant disease, an intravenous bisphosphonate and an anti-RANK ligand...
MEDICAL FRONTIERS - 6th International Conference on Thrombosis and Hemostasis Issues in Cancer
Treatment and Prevention of Venous Thrombosis in Cancer
Bergamo, Italy / April 20-22, 2012
Bergamo - Cancer is a hypercoagulable state where malignancy heightens thrombotic risk throughout the course of active disease, especially during metastases. Anti-angiogenic chemotherapy agents can significantly increase embolic risk, as...
MEDI-NEWS - Based on Canada Communicable Disease Report (CCDR) January 2012;37:ACS-7.
NACI Update on Human Papillomavirus (HPV) Vaccines: New Focus on Male Vaccination
In 2006, the quadrivalent human papillomavirus vaccine (HPV) was authorized in Canada for use in females between the ages of 9 and 26 years for the prevention of infection caused by HPV types 6, 11, 16 and 18. These types lead to cervical...
PRIORITY PRESS - 53rd Annual Meeting & Exposition of the American Society of Hematology
Enduring Survival Advantages of Novel Therapies for Transplant-ineligible Multiple Myeloma Patients
San Diego, California / December 10-13, 2011
San Diego - Prior to the introduction of proteasome inhibitors and immunomodulating agents for multiple myeloma (MM), the median survival for patients older than age 65 was <3 years. Five years after randomization, a 3-drug regimen with...
PRIORITY PRESS - 53rd Annual Meeting & Exposition of the American Society of Hematology
Targeted Therapy for Complement Inhibition: Preventing Life-threatening Thrombosis
San Diego, California / December 10-13, 2011
San Diego - Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) are 2 diseases driven by the complement system that respond to a monoclonal antibody (MAb) that binds to the human C5 complement protein and...